Denmark· DK-28104759610
Edurant
A rilpivirine product containing rilpivirinhydrochlorid, registered in Denmark by Janssen-Cilag International NV. The same ATC class is registered in 14 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Rilpivirine is registered in 14 of 19 countries.
Countries holding a registration under ATC J05AG05 (rilpivirine), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 9 of them publish a price we can compare per daily dose
Rilpivirine · ATC J05AG05
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rilpivirine costs, country by country.
Normalised to the WHO defined daily dose (25 mg), the median price runs from $6.77 in France to $13.46 in Switzerland — a ×2.0 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Rilpivirine · price per daily dose (25 mg)
USD · FX 28 Sept 2026
- CH Switzerland$13.46
- FR France$6.77
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Rilpivirinhydrochlorid
- Manufacturer
- Janssen-Cilag International NV
- Country
- Denmark (DK)
- ATC code
- J05AG05
- ATC class
- Rilpivirine
- Defined daily dose
- 25 mg, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28104759610
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
239 interactions on record for rilpivirine.
Graded by severity as the source publishes them — 58 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rilpivirine · interactions on record
239 records
- 58 severe
- 179 moderate
- 2 minor
Most severe, free to view
- CimetidineA02BA01severe
- RanitidineA02BA02severe
- FamotidineA02BA03severe
- NizatidineA02BA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J05AG05
Rilpivirine, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bddd056c-da1b-4b81-811d-7806217bccd3 GET /v1/drugs/bddd056c-da1b-4b81-811d-7806217bccd3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "filmovertrukne tabletter",
"source": "dkma",
"strength": "25 mg",
"auth_role": "MOD",
"dk_drugid": "28104759610",
"substance": "Rilpivirinhydrochlorid",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "40875"
}See everything about rilpivirine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.